Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 14.3% in July

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 114,100 shares, a growth of 14.3% from the June 30th total of 99,800 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 450,300 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH downgraded Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 18th.

Coeptis Therapeutics Trading Down 2.0 %

Shares of COEP traded down $0.01 during trading hours on Monday, reaching $0.25. 139,840 shares of the company’s stock traded hands, compared to its average volume of 334,473. Coeptis Therapeutics has a 12 month low of $0.23 and a 12 month high of $1.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.60 and a current ratio of 1.60. The firm’s 50 day simple moving average is $0.29 and its 200-day simple moving average is $0.38.

Coeptis Therapeutics (NASDAQ:COEP) last announced its earnings results on Friday, May 10th. The company reported ($0.08) earnings per share (EPS) for the quarter. Sell-side analysts expect that Coeptis Therapeutics will post -0.26 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC grew its position in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,520,000 shares of the company’s stock after purchasing an additional 1,308,000 shares during the period. Armistice Capital LLC owned about 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.